New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 15, 2015
10:29 EDTBAYRYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBAYRYAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
07:26 EDTBAYRYBayer expecting crops and seeds industry consolidation, Reuters reports
Subscribe for More Information
May 14, 2015
14:54 EDTBAYRYJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
May 13, 2015
18:43 EDTBAYRYBayer to present Xofigo, ODM-201 data at 2015 ASCO meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use